Flag Ranch event to feature musician Dave Tate, local artists and wineries Flag Ranch, a local non-profit focused on elevating the plight of horses, today announced its first fundraising event in its new home in Paso Robles. Flag Ranch is a horse + human collaboratory that takes in and cares for horses who would otherwise be euthanized while offering people opportunities for personal and professional growth through immersive experiences with the horses.
PASO ROBLES, Calif., Sept. 14, 2023 /PRNewswire-PRWeb/ — Flag Ranch, a local non-profit focused on elevating the plight of horses, today announced its first fundraising event in its new home in Paso Robles. Flag Ranch is a horse + human collaboratory that takes in and cares for horses who would otherwise be euthanized while offering people opportunities for personal and professional growth through immersive experiences with the horses.
The Pole Barn Benefit Concert will be held on their 50-acre property where the current herd of 50+ horses roam freely. The expansive pole barn will eventually be re-imagined as a gathering place for all kinds of activities from small group experiences, to an educational kitchen for culinary medicine classes, to film screenings and more – all amongst the horses!
Event Details Thursday, October 5, 6pm-9pm Tickets: $150 per person, available at flagranch.org/upcomingevents through September 20 Contact: Kimberly Carlisle, 650-868-7245, [email protected]
This event kicks off Flag Ranch’s fundraising campaign by featuring the beautiful voice and music of Dave Tate, the work of several local artists including sculptor Abigail Belknap and watercolorist Jenna Hutton and delicious plant-based pairings (with Pasta by Etto) from Pair With Chef Rachel and five fine wineries: Bristols (cider), Maha/Villa Creek, Maddox Meadery, The Royal Nonesuch Farm and Tribeca Wine Collective.
All proceeds benefit Flag Ranch and are partially tax-deductible. Kimberly Carlisle, Co-Founder and Executive Director, says, “We are loving our new home and thrilled to open our gates to our wonderful Paso Robles and SLO county community. In order for us to offer immersive and profound experiences with horses to more people, we need to build more inviting facilities. This benefit concert will be our first big step in doing so.”
In addition to providing a safe, natural and loving home for its animals, the ranch offers individuals, families, groups and teams the opportunity to interact with the horses to explore self-awareness and empowerment, develop creativity and intuition, and study their exemplary teamwork and leadership. All experiences take place on the ground; no prior horse experience is needed. For more information, visit flagranch.org.
“Being able to offer patients with increasingly diverse treatment needs the widest range of drug therapy options possible, has been a focus of our development and expansion,” said Eric Hill, co-founder of AvevoRx. “This latest deal with Takeda allows us to further deliver on that goal. It’s a testament to the clinical and management programs our teams have built and continue to refine.”
Added Justin Dent, national director of pharmacy operations for AvevoRx, “Adding CUVITRU to our portfolio of treatment options helps address the needs of a patient population that requires or benefits from receiving treatments subcutaneously. Meeting and supporting patients where they are, to maximize their comfort, safety, and effectiveness, remain our top priorities.”
AvevoRx is a bespoke, independent provider of specialty infusion pharmacy services. The company focuses on the highest-quality, personalized care customized to patients facing various complex, chronic disorders. Treatments are made available via specialized pharmacy locations, field nurses, and additional support staff throughout the United States. AvevoRx also provides acute infusion therapies for patients with short-term therapeutic needs on a regional basis. Privately held, the company was founded in 2021 by a small group of industry veterans with a combined experience of more than 130 years. AvevoRx is headquartered in North Carolina. To learn more, visit www.AvevoRx.com or follow us on Instagram or LinkedIn.
The study involved 620 diverse volunteers across the United States who were randomly assigned to take the placebo or one of two formulations of MDSleep containing federally legal limits of cannabinoids and other botanical ingredients. One MDSleep formulation contained lower amounts of THC per serving (.35 mg) and higher amounts of GABA and botanical oils, hops oil, and valerian oil. The second formulation contained higher amounts of THC per serving (.85 mg) and lower amounts of GABA, valerian, and hops oil, while the other botanicals (CBD, CBN, and L-Theanine) were in the same amounts as the first formulation.
Main Study Findings
When compared to placebo, MDSleep’s formulation with lower THC and higher amounts of select botanicals was shown to improve reported sleep quality, feelings of anxiety, stress, and overall well-being, with no serious side effects. When compared to placebo, this formulation showed:
A significant improvement in sleep quality (measured by the rate of mean change in the PROMIS™ Sleep Disturbance 8a score)
While not statistically significant, 57.3% of participants experienced a minimal clinically important difference (MCID) in their sleep quality relative to 42.2% of participants in the placebo group. (Note: A score reduction of one-half the standard deviation of the baseline score is considered a MCID).
A significant improvement in feelings of anxiety (measured by the rate of change in PROMIS™ Anxiety 4a score)
A significant improvement in feelings of stress (measured by the rate of change in the PROMIS™ Stress 4a score)
A significant improvement in well-being (measured by the rate of mean change in the World Health Organization (WHO)-5 Well-being index score)
There were no serious side effects reported in any study group and no significant differences in side effects between either MDSleep product group and the placebo.
This formulation of lower THC and higher select botanicals was clinically shown to:
Improve sleep disturbance (sleep quality)
Enhance sleep onset
Support restful and healthy sleep
Improve feeling well-rested upon waking
Reduce feelings of anxiety and stress
Promote well-being
The formulation with higher cannabinoids and lower amounts of select botanicals did not show significant differences in any of these measures.
“Our commitment to medical-grade botanical formulations is reflected in the results of this study, which shows how precision dosing of multiple ingredients (polypharmacology) makes a significant difference in clinical effectiveness. We are thrilled that the medical community can now proudly recommend a clinically proven sleep aid that is backed by the scientific rigor we expect as practitioners,” shared Dr. Babak Larian, MD, FACS; Co-Founder of MDbio – The Doctors Brand™.
Receiving statistical clinical significance in one category, let alone four categories, proves that MDbio’s unicorn approach to formulation and commitment to patient outcomes is not only a highly effective method, but creates a new baseline for what is acceptable in the supplement industry.
Dr. Emily Pauli, PharmD, Chief Research Officer of Radicle Science™, explained, “This study suggests that lower levels of THC in combination with CBD, CBN, and higher levels of GABA and GABA-elevating botanical oils from valerian and hops, may improve sleep quality. While further exploration is necessary, this research supports the idea of synergism between botanical compounds, allowing for variable amounts of them without additional side effects. It highlights the importance of methodical formulation development and testing through rigorous clinical trials such as Radicle Rest.”
Dr. Jeff Chen, MD, Cofounder/CEO of Radicle Science™ shared, “Also notable is that neither formulation contained melatonin, which has recently received national concern for dangerous lack of accuracy. In many other countries like England, melatonin requires a prescription, while in other countries like Japan, melatonin is banned. Thus it is particularly important that Americans have non-melatonin sleep aids that are clinically effective, and MDSleep is now a proven new option for the sleep market.”
This is just the beginning for MDbio – The Doctors Brand™. MDbio enters the market perfectly positioned to disrupt both the pharmaceutical and nutraceutical spaces by displacing many formulations that either have significant side effects or no clinical efficacy. Their commitment to a scientific approach to validate formulations introduces a new standard for the supplement industry where consumers won’t have to choose between harsh side effects and non-effective products.
With clinical trials currently underway for other MDbio products and a robust formulation pipeline that includes non-hemp botanical variations, we can expect to see more from this emerging leader in the very near future.
About MDbio – The Doctors Brand™: MDbio – The Doctors Brand™ was founded by four renowned medical doctors committed to providing therapeutic alternatives to pharmaceutical drugs. MDbio provides medical-grade, patient-tested plant-based medicine products that are unique in the industry for their innovation, quality, and scientific rigor. Targeting ailments such as poor sleep, stress/anxiety, pain, and weakened immune system, MDbio products naturally restore balance and promote healing to maximize overall health and wellbeing in patients. Founders of MDbio include:Kiarash Michel, MD; Babak Larian, MD, FACS; Siamak Tabib, MD and Kamran Jamshidinia, DPM, FACFAS. To learn more, please visit mdbiowellness.com.
About Radicle Science™: Radicle Science™ is history’s first Proof-as-a-Service company, enabling non-prescription health and wellness products to clinically prove their true effects beyond placebo. The B-corp offers non-pharmaceutical products the first easy path to generate first-of-its-kind clinical evidence across diverse conditions and populations at unprecedented affordability, speed, and scale. Radicle’s transformative approach democratizes access to clinical trials and can finally close the “proof gap” between non-prescription wellness products and pharmaceutical drugs. To learn more, please visit radiclescience.com
According to the National Institute of Health, cosmetic body sculpting surgery continues to rise in widespread national popularity, with research suggesting that North America experienced an upshoot in liposuction surgery interest amid the COVID-19 pandemic. The National Institute of Health reported an increase in individuals interested in plastic surgery as a result of an increase in social media ads for plastic surgery.
NYC Liposuction Surgery Specialists (Midtown, Manhattan, NY) is a specialty plastic surgery practice in NYC which exclusively provides liposuction plastic surgery (with or without fat transfer) and body contouring / body sculpting. The board certified NYC liposuction plastic surgeons offer Lipo 360, high-definition liposuction, micro liposuction, power-assisted liposuction, liposuction with radiofrequency (RF) BodyTite®, SmartLipo, super wet liposuction, “traditional” liposuction, tumescent liposuction, and VASER high-def liposuction. The liposuction plastic surgery procedure which will be best for the patient depends on the patients unique anatomy and post-surgical goals. All liposuction plastic surgery procedures are customized to each patient.
Fellows will develop solutions for the most urgent challenges facing young Indians under 30, such as public health, sustainability, the future of the workforce, digital disruption, and gender equality.
NEW DELHI, Sept. 14, 2023 /PRNewswire-PRWeb/ — The United Nations Foundation (UN Foundation) and the Council on Energy, Environment and Water (CEEW, India) today announced the Next Generation India Fellowship on the sidelines of India’s G20 presidency. The Fellowship is an opportunity for young Indian thinkers and leaders to gain first-hand experience in understanding and solving the world’s most pressing challenges.
The Next Generation India Fellowship — part of the UN Foundation’s Our Future Agenda programme and CEEW’s focus on building careers in public policy — is specifically designed to unlock original, maverick, and substantive ideas from the youth of India for a sustainable future.
“The Next Generation India Fellowship is not just about learning, it is about transforming global leadership and impact,” shared Elizabeth Cousens, President and CEO of the UN Foundation. “The Fellows will have the chance to engage with and learn from global leaders, policymakers, and influencers, gaining insight and contributing their ideas into key processes that shape world affairs.”
Spanning two years, the Fellowship will foster honest conversations about the ‘One Future’ theme of the G20 presidency, build consensus around a ‘future agenda’ for young Indians, and explore options for investing in their generation and protecting the needs and rights of future generations.
The Fellowship will also provide an opportunity to strengthen youth-led and youth-focused networks and platforms, and contribute towards institution building. It will provide a platform for the Fellows during India’s G20 presidency, the SDG Summit, and the Summit of the Future to communicate their proposals, advocate for key asks, share models for inspiration and action, and forge collaborations between countries of the Global North and the Global South.
“These exceptional individuals will be at the forefront of championing the cause of 21st-century multilateralism, driving forward a vision of collaboration, inclusivity, progress and sustainability – for all,” stated Dr Arunabha Ghosh, Chief Executive Officer of CEEW. “It aims to provide young Indian changemakers a global platform to voice their ideas and influence key discussions across international organisations.”
The Fellowship includes a diverse range of focus areas including public health, sustainable cities, new technologies, culture and communities, gender equality, future of the workforce, affordable and clean energy, and oceans. Fellows will gain a deeper understanding of policy making, strategic planning, and global diplomacy guided by the experience and mentorship of the UN Foundation, CEEW, and partner resources.
The partnership between the UN Foundation and CEEW provides an opportunity to recognise the potential of young minds and equip them with the skills, aptitude, and confidence needed to address present and future global challenges. It has been supported by Mr. Narayana Murthy and Mrs. Sudha Murty through a contribution made to CEEW directly in Indian rupees.
For 25 years, the UN Foundation has built novel innovations and partnerships to support the United Nations and help solve global problems at scale. As an independent charitable organization, the Foundation was created to work closely with the United Nations to address humanity’s greatest challenges and drive global progress. Learn more at http://www.unfoundation.org and http://www.ourfutureagenda.org.
About the Council on Energy, Environment and Water
The Council on Energy, Environment and Water (CEEW), based in India, is one of Asia’s leading not-for-profit policy research institutions. The Council uses data, integrated analysis, and strategic outreach to explain – and change – the use, reuse, and misuse of resources. It prides itself on the independence of its high-quality research, develops partnerships with public and private institutions, and engages with the wider public. In 2021, CEEW once again featured extensively across ten categories in the 2020 Global Go To Think Tank Index Report. The Council has also been consistently ranked among the world’s top climate change think tanks. Follow us on Twitter @CEEWIndia for the latest updates.
DUBLIN, Sept. 14, 2023 /PRNewswire/ — The “Veterinary Telehealth Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering. The global veterinary telehealth market is expected to grow from $3.15 billion in 2022 to $3.77 billion in 2023 at a compound annual…
ZÜRICH, Sept. 14, 2023 /PRNewswire/ — Earlier this year, Neoss Group, a pioneer in dental implant solutions, announced a partnership with Osstell AB, a global leader in implant stability measurement and osseointegration progress monitoring. Today, we proudly introduce the first fruit of…
Most recently, Pussinen served as Chief Technical Officer for Spark Therapeutics, Inc., a fully integrated, commercial gene therapy company, and a member of the Roche Group. Prior to joining Spark in 2021, Pussinen’s leadership roles included six years with Ipsen Biomeasure and Ipsen Biosciences, U.S. R&D-focused subsidiaries of Ipsen, where she served as President and CEO. Pussinen previously served as Executive Vice President, Technical Development, Operations and Supply Chain for Actinium Pharmaceuticals, Inc. and as Global Vice President and General Manager, Life Sciences and Specialty Chemicals for Honeywell International.
“Cynthia Pussinen is an extremely accomplished and respected scientist and global pharmaceutical executive with an impressive track record of bringing innovative new products to market in various leadership roles at several highly acclaimed life sciences companies,” said Leslie Loveless, Slone Partners CEO. “She will make for a terrific addition to the Sernova leadership team and Board of Directors during a pivitol stage in the company’s evolution.”
“Sernova has demonstrated tremendous growth over the past several years as it has transitioned from a research company to one that is moving towards commercialization of a product for the treatment of multiple chronic diseases. As a united Board, we feel now is the time to bring in an industry leader with extensive experience with large pharmaceutical companies as well as entrepreneurial biotech and advanced therapeutics focused companies,” commented Brett Whalen, Chair of the Board of Directors of Sernova. “The skills that Ms. Pussinen brings to our company include over 25 years of global experience shepherding new therapies from development through commercialization across multiple conditions with sales measured in the billions.”
Pussinen earned a Master of Science in R&D management from Rensselaer Polytechnic Institute and a Bachelor of Science in chemistry, with a minor in engineering from the University of Connecticut.
ABOUT SLONE PARTNERS Founded in 2000, Slone Partners is the premier executive search firm that delivers top diverse and visionary leaders who build amazing life sciences, healthcare, and cybersecurity organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class C-Suite leadership, executive, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes diversity, equity, and inclusion strategy, education, and training. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.
ABOUT SERNOVA CORPORATION Sernova Corporation is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need for chronic, systemic immunosuppression. For more information, visit the website: https://sernova.com/.
“We are very excited about our new lab space,” exclaims Dr. Byrn, CSO of Improved Pharma. “We will be able to house additional instrumentation and perform required experiments that are critical for development of compounds into life-saving drugs.”
About Improved Pharma Improved Pharma is a research and information company dedicated to improving pharmaceutical methods, formulations, and processes. Services include solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting for the development and defense of intellectual property matters. The company was founded in 2006 by Stephen and Sarah Byrn, who also founded SSCI.
NEW YORK, Sept. 14, 2023 /PRNewswire/ — The dental loupe market size is expected to grow by USD 125.58 million from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 7% during the forecast period, according to Technavio Research. The market is segmented by…
